Epstein Secrets

50 - currently at 861.00 down 2.3% from purchase please advise thank you Richard Kahn HBRK Associates Inc. Begin forwarded message: From: "Ens, Amanda" Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pricing

. Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and is protected by five patents: '250, '413, '302, '776 and '874, which expire on 8/19/30. Today's IPR

rently at 861.00 down 2.3% from purchase please advise thank you Richard Kahn HBRK Associates Inc. tee= fa Begin forwarded message: From: "Ens, Amanda" < Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn Rich, With yesterday's weakness in healthcare on pricin

. Links to Notes • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (from Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and is protected by five patents: '250, '413, '302, '776 and '874, which expire on 8/19/30. Today's IPR

mages: image0Ol.png Richard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York. NY 10022 cc Begin forwarded message: From: -Ens, Amanda' •z > Subject: Allergen and Teva Date: July 28, 2016 at 9:08:09 AM EDT To: Richard Kahn ‹ > Rich, Regarding biotech, our traders mentioned they

uct diversity are increasingly Important. • Our updated model is conservative vs. TEVA's issued 2017-19 outlook as we assume generic competition to Copaxone 3TW in '17. Company Description Teva, an Israeli/US generics company, is one of the largest companies in the global generic pharma industry and is beco

ard Kahn HBRK Associates Inc. 575 Lexington Avenue 4th Floor New York NY 10022 tel fax cell Begin forwarded message: EFTA00665656 From: "Ens, Amanda" < Subject: Add to TEVA and AGN Date: August 25, 2016 at 9:35:43 AM EDT To: Richard Kahn c > Rich, With yesterday's weakness in healthcare on pr

s EFTA00665657 • Link to TEVA Note • Link to MYL Note • Link to MNTA Note Quick Background on Copaxone 3TW Litigation (front Sumant's note) Copaxone 3TW has new product exclusivity through 1/28/17 and is protected by five patents: '250, '413, '302, '776 and '874, which expire on 8/19/30. Today's IPR